title: The combined effect of topical CX-659S, a novel diaminouracil derivative, with topical corticosteroid on the three types of allergic responses in mice or guinea pigs.
abstract: CX-659S ((S)-6-amino-5-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)-3-methyl-1-phenyl-2,4(1H,3H)-pyrimidinedione), a newly discovered anti-inflammatory compound, exerts inhibitory effects against picryl chloride-, oxazolone-, and dinitrochlorobenzene-induced acute contact hypersensitivity responses (CHRs) characterized by Th1-type reactions. Furthermore, this compound suppressed chronic CHRs characterized by Th2-type reactions, which is well known to mimic many, if not all, events occurring within the lesional skin of patients with atopic dermatitis (AD). The present study was conducted to determine the combined effect of topical CX-659S with topical corticosteroid on immediate type (ITR), late type (LTR), and delayed type hypersensitivity (DTHR) allergic reactions that are involved in AD. An ineffective dose of CX-659S (0.03 mg/ear) combined with betamethasone valerate (BV) significantly potentiated inhibitory activity of BV alone (0.1 micro g/ear and 0.3Shizuokag/ear) on both the ITR and the LTR in mice with the ovalbumin (OVA)-induced biphasic cutaneous reaction. Furthermore, the combined effect of CX-659S with BV was also observed on dinitrochlorobenzene (DNCB)-induced DTHR in guinea pigs. These results indicate that CX-659S has a combined effect with corticosteroids on every ITR, LTR, and DTHR. Proper treatment with corticosteroids for a safe and effective treatment of AD is needed. Thus, the combination therapy of topical CX-659S with topical corticosteroid would be one of the potential approaches for devising a proper treatment with corticosteroids.
authors.affiliation: Pharmaceuticals and Biotechnology Laboratory, Japan Energy Corporation, Saitama, Japan.
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Inoue
authors.forename: Masakazu
authors.initials: M
authors.lastname: Isobe
authors.forename: Hideya
authors.initials: H
authors.lastname: Hayashi
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D001624:Betamethasone Valerate / Q000008:administration & dosage / Q000494:pharmacology*; D003877:Dermatitis, Contact / Q000188:drug therapy* / Q000473:pathology; D004137:Dinitrochlorobenzene / Q000494:pharmacology; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed / Q000188:drug therapy; D006969:Hypersensitivity, Immediate / Q000188:drug therapy; D007202:Indicators and Reagents; D007509:Irritants / Q000494:pharmacology; D051379:Mice; D008813:Mice, Inbred ICR; D010047:Ovalbumin / Q000276:immunology; D012867:Skin / Q000473:pathology; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004137:Dinitrochlorobenzene; D007202:Indicators and Reagents; D007509:Irritants; D014498:Uracil; D010047:Ovalbumin; D001624:Betamethasone Valerate; C418807:CX 659S